Literature DB >> 24283425

Guillain-Barré syndrome with severe persistent disability: relationship to hyperacute Guillain-Barré syndrome.

J A Palace1, R A Hughes.   

Abstract

Guillain-Barré syndrome (GBS) is a heterogeneous condition with a variable prognosis. We studied nine patients who were unable to walk unaided 12 months after the onset of their illness to discover whether they belonged to a more homogeneous subgroup. Sis of the nine patients had symptoms of gastroenteritis shortly before the onset of their neuropathic symptoms and a hyperacute onset of weakness so that they were bed-bound within 24 h. These patients had predominantly motor rather than sensory involvement We compared these nine poor outcome patients with 66 patients with lesser degrees of persistent disability of whom only three had both a history of prodromal gastroenteritis and a hyperacute onset (p < 0.0001). The poor and better outcome groups did not differ significantly in the severity of disability or other clinical or neurophysiological features in the acute stage. Patients with previous gastroenteritis and hyperacute onset of weakness may represent a relatively homogeneous subgroup of "hyperacute GB" in which severe axonal damage is caused by an aberrant immune response to a gastrointestinal pathogen such as Campylobacter jejuni. 1994 Lippincott Williams & Wilkins.

Entities:  

Year:  1994        PMID: 24283425     DOI: 10.1111/j.1468-1331.1994.tb00046.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  3 in total

1.  Rate of progression of Guillain-Barré syndrome is not associated with the short-term outcome of the disease.

Authors:  Mirjana Arsenijević; Ivana Berisavac; Branka Mladenović; Predrag Stanarčević; Dejana Jovanović; Dragana Lavrnić; Stojan Peric
Journal:  Ir J Med Sci       Date:  2020-07-14       Impact factor: 1.568

2.  Risk Prediction Models for Early ICU Admission in Patients With Autoimmune Encephalitis: Integrating Scale-Based Assessments of the Disease Severity.

Authors:  Chunmei Wu; Yongkang Fang; Yingying Zhou; Huiting Wu; Shanshan Huang; Suiqiang Zhu
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

Review 3.  Guillain-Barré syndrome. Clinical manifestations and directions for treatment.

Authors:  J Rees
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.